Infinity Pharmaceuticals, Inc.
http://www.infi.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Infinity Pharmaceuticals, Inc.
Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Roche Goes Big On KRAS-Mutated Cancers In Hookipa Pact
Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.
Finance Watch: With Limited Fundraising Options, Biotechs Restructure To Extend Cash Runways
Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice